Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04222972
Title A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (AcceleRET-Lung)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Blueprint Medicines Corporation
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | NZL | NLD | ITA | GBR | FRA | ESP | DEU | BEL | AUS

Additional content available in CKB BOOST